News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Insight Genetics Awarded New National Cancer Institute Contract To Identify Resistance Mutations In Lung Cancer Patients


1/6/2014 11:26:44 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Nashville, Tenn., January 6, 2013 – Insight Genetics, Inc. today announced it has received a new $1.5 million Phase II Small Business Innovation Research (SBIR) contract from the National Cancer Institute (NCI). A continuation of a Phase I contract NCI awarded to Insight Genetics in 2011, the new contract will allow the company to continue its development of Insight ALK Resistance™, a diagnostic test that helps clinicians monitor their non-small cell lung cancer (NSCLC) patients for resistance to their prescribed cancer therapy.

“Resistance is a growing concern in the cancer treatment world,” said Eric Dahlhauser, Chairman and CEO of Insight Genetics. “The Insight ALK Resistance assay meets a significant unmet need in non-small cell lung cancer by giving physicians a way to monitor their patients for drug resistance and providing information to help them determine the most effective course of treatment. Our team is delighted to continue our collaboration with the NCI to create companion diagnostic tests that can enhance how cancer is diagnosed, treated and monitored.”

Targeted therapeutics have been developed that effectively inhibit known genetic drivers of NSCLC such as EGFR and anaplastic lymphoma kinase (ALK). However, most patients develop resistance to their prescribed inhibitor within a year, making it no longer effective. Inhibitor resistance is driven by mutations in either the primary oncogenic gene or a separate gene in a secondary pool of cancer cells. Identification of the genetic driver of a patient’s inhibitor resistance can help a physician choose the appropriate ongoing treatment for the patient, which could include a next-generation inhibitor or other therapy that targets a separate oncogenic driver.

Insight ALK Resistance is a qPCR-based test that is customizable to detect all clinically identified resistance mutations in the ALK kinase domain or specific mutations, providing results within 48 hours and with minimal tissue requirement. The test can be used for various applications, including providing guidance in monitoring treatment efficacy, clinical decision making for alternative treatments, clinical trial enrollment for next-generation ALK inhibitors, or investigational academic research. Insight Genetics has obtained an exclusive worldwide license from St. Jude Children’s Research Hospital for the detection of ALK inhibitor resistance mutations.

This SBIR award is Insight Genetics’ sixth contract and third consecutive Phase II contract from NCI’s Companion Diagnostics program. It will allow Insight Genetics to further refine Insight ALK Resistance toward a Premarket Approval Application (PMA) with the U.S. Food and Drug Administration.

Insight ALK Resistance is currently offered by Insight Molecular Labs, the CLIA-certified subsidiary of Insight Genetics, as a laboratory-developed test. Insight Molecular Labs provides support services for clinical trials on targeted therapeutics, including the identification of appropriate patients for trials, and specializes in the detection and monitoring of molecular-driven drug resistance in patients being treated with specific cancer therapies.

About Insight Genetics

Insight Genetics is dedicated to improving the lives of cancer patients through advanced molecular diagnostics that enable precision in cancer care. The company specializes in the discovery, development and commercialization of companion diagnostics that detect specific cancer biomarkers and assist in guiding the effective diagnosis and treatment of cancer. Insight Genetics is ISO 9001:2008 certified and partners with leading academic researchers, pharmaceutical and biotechnology companies, clinical reference laboratories, and IVD kit manufacturers to create new standards of care for cancer patients worldwide. Visit www.insightgenetics.com for more information.

Contact:

Samantha Fiala

615-327-7999

sfiala@seigenthaler.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES